Similarly, mutations in splicing regulators such as serine/arginine-rich splicing factor 2 (SRSF2) drive hematological malignancies, including myelodysplastic syndrome (MDS) [104, 105]. The gene discussed is SRSF2; the disease is myelodysplastic syndrome.